Inhibition of rat vascular smooth muscle cell proliferation in vitro and in vivo by recombinant replication-competent herpes simplex virus

Stroke

Volumn 30, Issue 11, 1999, Pages 2431-2439

  Miyatake, Shin Ichi ^a   Yukawa, Hiroyuki ^a   Toda, Hiroki ^a   Matsuoka, Norihiro ^a   Takahashi, Rei ^a   Hashimoto, Nobuo ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Balloon embolization; Herpesvirus; Muscle, smooth

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; HERPES SIMPLEX VIRUS; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RAT; RESTENOSIS; VASCULAR SMOOTH MUSCLE; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 0032723958     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.11.2431     Document Type: Article

References (45)

1. Zierler RE, Bandyk DF, Thiele BL, Strandness DE Jr. Carotid artery stenosis following endarterectomy. Arch Surg. 1982;117:1408-1415.
2. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med. 1986;314:488-500.
3. Leimgruber PP, Roubin GS, Hollman J, Cotsonis GA, Meiter B, Douglas JS, King SB, Gruentzig AR. Restenosis after successful coronary angio-plasty in patients with single-vessel disease. Circulation. 1986;73: 710-717.
4. Gruentzig AR, King SB, Schlumpf M, Siegenthaler W. Long-term follow-up after percutaneous transluminal coronary angioplasty: the early Zurich experience. N Engl J Med. 1987;316:1127-1132.
5. Becker GJ, Katzen BT, Dake MD. Noncoronary angioplasty. Radiology. 1989;170:921-940.
6. Touho H. Percutaneous transluminal angioplasty in the treatment of atherosclerotic disease of the anterior cerebral circulation and hemodynamic evaluation. J Neurosurg. 1995;82:953-960.
7. Ferns GAA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991;253:1129-1132.
8. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A. 1991;88:3739-3743.
9. Epstein SE, Siegall CB, Biro S, Fu YM, Fitzgerald D, Pastan I. Cytotoxic effects of a recombinant chimeric toxin on rapidly proliferating vascular smooth muscle cells. Circulation. 1991;84:778-787.
10. Simons M, Edelman ER, DeKayser JL, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 1992;359:67-70.
11. Biro S, Siegall CB, Fu YM, Speir E, Pastan I, Epstein SE. In vitro effects of a recombinant toxin targeted to the FGF receptor on rat vascular smooth muscle and endothelial cells. Circ Res. 1992;71:640-645.
12. Casscells W, Lappi DA, Olwin BB, Wai C, Siegman M, Speir E, Sasse J, Baird A. Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors. Proc Natl Acad Sci U S A. 1992;89:7159-7163.
13. Speir E, Epstein SE. Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the mRNA encoding PCNA. Circulation. 1992;86:538-547.
14. Simons M, Rosenberg RD. Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ Res. 1992;70:835-843.
15. Biro S, Fu YM, Yu ZX, Epstein SE. Inhibitory effects of antisense oligonucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci U S A. 1993;90:654-658.
16. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A. 1993;90: 8474-8478.
17. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, Nabel EG. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science. 1994;265:781-784.
18. Miyatake S, Iyer A, Martuza RL, Rabkin SD. Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol. 1997;71: 5124-5132.
19. Miyatake S, Tani S, Feigenbaum F, Sundaresan P, Toda H, Narumi O, Kikuchi H, Hashimoto N, Hangai M, Martuza RL, Rabkin SD. Hepatoma-specific anti-tumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther. 1999;6:564-572.
20. Kogishi J, Miyatake S, Hangai M, Akimoto M, Okazaki K, Honda Y. Mutant herpes simplex virus-mediated suppression of retinoblastoma. Curr Eye Res. 1999;18:321-326.
21. Martuza RL, Malick A., Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991;252:854-856.
22. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multimutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1:938-943.
23. Chambers R, Gillespie GY, Soroceanu L, Andreansky S, Chatterjee S, Chou J, Roizman B, Whitley RJ. Comparison of genetically engineered herpes simplex virus for the treatment of brain tumors in a scid mouse model of human glioma. Proc Natl Acad Sci U S A. 1995;92:1411-1415.
24. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, Roizman B, Whitley RJ. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 1997;57:1502-1509.
25. Thelander L, Reichard P. Reduction of ribonucleotide. Annu Rev Biochem. 1979;48:133-158.
26. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 1acZ insertion mutant. J Virol. 1988;62:196-205.
27. Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology. 1988;166:41-51.
28. Chamley JH, Campbell GR, McConnell JD, Groschel Stewart U. Comparison of vascular smooth muscle cells from adult human, monkey and rabbit in primary culture and in subculture. Cell Tissue Res. 1977;177: 503-522.
29. Guzman RJ, Lemarchand P, Crystal RG, Epstein SE, Finkel T. Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circulation. 1993;88:2838-2848.
30. Stel HV, van der Kwast TH, Veerman EC. Detection of factor VIII/ coagulant antigen in human liver tissue. Nature. 1983;303:9-15.
31. Gerdes J, Lemke H, Baish H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-1715.
32. Yukawa H, Miyatake SI, Saiki M, Takahashi JC, Mima T, Ueno H, Nagata I, Kikuchi H, Hashimoto N. In vitro growth suppression of vascular smooth muscle cells using adenovirus-mediated gene transfer of a truncated form of fibroblast growth factor receptor. Atherosclerosis. 1998;141:125-132.
33. Hanna AK, Fox JC, Neschis DG, Safford SD, Swain JL, Golden MA. Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. J Vasc Surg. 1997;25:320-325.
34. Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Nabel EG. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518-522.
35. Nakaoka T, Gonda K, Ogita T, Otawara-Hamamoto Y, Okabe F, Kira Y, Harii K, Miyazono K, Takuwa Y, Fujita T. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J Clin Invest. 1997;100:2824-2832.
36. Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG, Epstein SE, Finkel T. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci U S A. 1994;25: 10732-10736.
37. Coen DM, Kosz-Vnenchak M, Jacobson JG, Leib DA, Bogard CL, Schaffer PA, Tyler KL, Knipe DM. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci U S A. 1989;86:4736-4740.
38. Field HJ, Wildy P. The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J Hyg. 1978;81:267-277.
39. Field HJ, Coen DM. Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene. J Virol. 1986;60:286-289.
40. Pyles RB, Sawtell NM, Thompson RL. Herpes simplex virus type 1 dUTPase mutants are attenuated for neurovirulence. J Virol. 1992;66: 6706-6713.
41. Department of Health, and Human Services. Recombinant DNA Advisory Committee National Institutes of Health: minutes of meeting, June 18-19, 1998. Hum Gene Ther. 1999;10:489-533.
42. Department of Health, and Human Services. Recombinant DNA Advisory Committee National Institutes of Health: minutes of meeting, June 18-19, 1998. Hum Gene Ther. 1999;10:489-533.
43. Liu MW, Roubin GS, King III SB. Restenosis after coronary angioplasty: potential biologic determinants and role of intimai hyperplasia. Circulation. 1989;79:1374-1387.
44. Coen DM, Goldstein DJ, Weller SK. Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir. Antimicrob Agents Chemother. 1989;33:1395-1399.
45. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using gancyclovir-hypersensitive ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 1994;54:3963-3966.